Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness

af Molderings, G. J., Dumoulin, F. L., Homann, J., Sido, B., Textor, J., Mücke, M., Qagish, G. J., Barion, R., Raithel, M., Klingmüller, D., Schäfer, V. S., Hertfelder, H. J., Berdel, D., Tridente, G., Weinstock, L. B., Afrin, L. B.
Udgivet i Naunyn Schmiedebergs Arch Pharmacol (2020)